- NIH Implementation of Final Research Performance Progress Reports (Final RPPR) for Small Business and Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grants and Cooperative Agreements (NOT-OD-17-085)
  National Institutes of Health
- Findings of Research Misconduct (NOT-OD-17-088)
  National Institutes of Health
- Notice of Extension of PAR-14-294 "Arts-Based Approaches in Palliative Care for Symptom Management (R01)" (NOT-AT-17-013)
  National Center for Complementary and Integrative Health, National Institute of Nursing Research
- Notice of NCI's Participation on PA-17-225 "Advancing the Science of Geriatric Palliative Care (R01)" (NOT-CA-17-054)
  National Cancer Institute
- Notice of Correction to PA-17-110, "Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)" (NOT-CA-17-063)
  National Cancer Institute, National Institute on Aging
- Notice of Early Expiration of PAR-15-306 "Lymphatics in Health and Disease in the Digestive System, Kidney, and Urinary Tract (R01)" (NOT-DK-17-014)
  National Institute of Diabetes and Digestive and Kidney Diseases
- Salary Limitation on AHRQ FY2017 Grants, Cooperative Agreements, and Contracts (NOT-HS-17-017)
  Agency for Healthcare Research and Quality
- Request for Information: Rigor, Reproducibility and Statistical Power in Mental Health Research (NOT-MH-17-036)
  National Institute of Mental Health
- Notice of Change to Key Dates for PAR-17-309 "Cellular and Molecular Biology of Complex Brain Disorders (R01)" (NOT-MH-17-037)
  National Institute of Mental Health
- Notice of Change to Key Dates for PAR-17-310 "Cellular and Molecular Biology of Complex Brain Disorders (R21)" (NOT-MH-17-038)
  National Institute of Mental Health
- Notice of NINR's Participation on PA-17-194 "Targeted Implementation Science to Achieve 90/90/90 Goals for HIV/AIDS Prevention and Treatment (R01)" (NOT-NR-17-020)
  National Institute of Nursing Research
- Notice of NINR's Participation on PA-17-182 Notice Title, "Innovations in HIV Testing, Adherence, and Retention to Optimize HIV Care Continuum Outcomes (R01)" (NOT-NR-17-022)
  National Institute of Nursing Research
- Revision: Guidance on Salary Limitation for Grants and Cooperative Agreements (NOT-OD-17-087)
  National Institutes of Health
- Notice of Change in Receipt Dates for PAR-14-182 "Exploratory Clinical Trials of Mind and Body Interventions for NCCAM High Priority Research Topics (R34)" (NOT-AT-17-014)
  National Center for Complementary and Integrative Health
- Notice of Change in Application Due Date for RFA-CA-17-027 "Pediatric Early Phase Clinical Trials Network (UM1)" (NOT-CA-17-072)
  National Cancer Institute
- Notice of Correction to RFA-CA-17-011 "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)" (NOT-CA-17-073)
  National Cancer Institute
- Notice of Correction to RFA-CA-17-012 "Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)" (NOT-CA-17-074)
  National Cancer Institute
- Notice of Modifications to PAR-17-068 "Maximizing Access to Research Careers Undergraduate - Student Training in Academic Research (MARC U-STAR) (T34)" (NOT-GM-17-011)
  National Institute of General Medical Sciences
- Notice of Frequently Asked Questions for PAR-17-294 "Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans Resource Access (X01)"
National Heart, Lung, and Blood Institute

- Notice of Frequently Asked Questions for RFA-HL-18-008 "Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34)"
- Notice of Intent to Reissue the Funding Opportunity Announcement for the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00)

National Institute of Neurological Disorders and Stroke
National Center for Complementary and Integrative Health
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute of Nursing Research
Office of Behavioral and Social Science Research

- Notice of Pre-Application Webinars for the High-Risk, High-Reward Research Program's Pioneer (RFA-RM-17-005), New Innovator (RFA-RM-17-006), Transformative Research (RFA-RM-17-007), and Early Independence (RFA-RM-17-008) Awards

NIH Roadmap Initiatives

- Notice of Correction of the Anticipated Announcement and Award Dates in RFA-RM-17-006 NIH Director's New Innovator Award Program (DP2)

National Institutes of Health

- Revision: Ruth L. Kirschstein National Research Service Awards (NRSA) Predoctoral Stipends, Training Related Expenses, Institutional Allowance, and Tuition/Fees Effective for Fiscal Year 2017

National Institutes of Health

- NIH Fiscal Policy for Grant Awards - FY 2017

National Institutes of Health

- Development, Integration, and Data Mining of Biomolecular and Cellular Networks for Discovering Druggable Targets for Alcohol Use Disorder and Alcohol-Induced Organ Damage

National Institute on Alcohol Abuse and Alcoholism

- Notice of Change to Key Dates in PA-17-291 "HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01)"

National Institute of Allergy and Infectious Diseases

- Notice of NEI Participation in NOT-AA-17-005 "Request for Information (RFI): National Institute on Alcohol Abuse and Alcoholism (NIAAA) Initiative for Collecting, Archiving, and Sharing Individual-Level Human Subjects Data"

National Eye Institute

- Notice of Intent to Participate in the Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences

National Institute of General Medical Sciences

- Notice of Intent to Publish a Funding Opportunity Announcement for Data Analysis and Coordinating Center, Multicenter AIDS Cohort Study/ Womens Interagency HIV Study Combined Cohort (U24)

National Heart, Lung, and Blood Institute

- Notice of Intent to Publish a Funding Opportunity Announcement for Field Centers, Multicenter AIDS Cohort Study/ Womens Interagency HIV Study Combined Cohort (U01)

National Heart, Lung, and Blood Institute

- Notice of Clarity for Other Attachments in PAR-17-081, "NIMH Research Education Programs for Psychiatry Residents (R25)"

National Institute of Mental Health
REQUEST FOR APPLICATIONS

- **TITLE:** Development of a Device to Objectively Measure Pain (R41/R42)
  **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
  **Synopsis:** The purpose of this Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) is to develop a technology/device that objectively indicates the presence and level of pain. These tools could additionally help to measure:
  - The original or type of pain (e.g. nociceptive, neuropathic, centrally mediated...).
  - The type of treatment that might be most effective in alleviating pain.
  - Whether opioids might be useful versus if it may present significant risks.
  This technology/device should be affordable and usable within many clinical settings including primary care. There have been many recent advances in measuring variables that predict if a person is in chronic pain, including blood factors, facial expressional, and eye reactivity. The new technology could measure some of these variables, or other appropriate variables.
  Application Receipt Date(s): December 5, 2017

- **TITLE:** Development of a Device to Objectively Measure Pain (R34/R43)
  **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
  **Synopsis:** The purpose of this Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) is to develop a technology/device that objectively indicates the presence and level of pain. These tools could additionally help to measure:
  - The original or type of pain (e.g. nociceptive, neuropathic, centrally mediated...).
  - The type of treatment that might be most effective in alleviating pain.
  - Whether opioids might be useful versus if it may present significant risks.
  This technology/device should be affordable and usable within many clinical settings including primary care. There have been many recent advances in measuring variables that predict if a person is in chronic pain, including blood factors, facial expressional, and eye reactivity. The new technology could measure some of these variables, or other appropriate variables.
  Application Receipt Date(s): December 5, 2017

- **TITLE:** Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01)
  **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.
  Application Receipt Date(s): Multiple dates, see announcement

- **TITLE:** Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA)
  **SPONSOR:** United States Department of Defense (DOD), Department of the Army, U.S. Army Medical Research and Materiel Command (USAMRMC), Office of Congressionally Directed Medical Research Programs (CDMRP)
  **Synopsis:** The mission of the FY17 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.
  Application Receipt Date(s): September 7, 2017

- **TITLE:** Scholar in Clinical Research Awards
  [http://www.lls.org/research/career-development-program](http://www.lls.org/research/career-development-program)
  **SPONSOR:** Leukemia & Lymphoma Society (LLS)
  **Synopsis:** Through the Career Development Program, LLS supports talented blood cancer researchers in the early phase of their careers. CDP continues to provide a pool of dedicated researchers to advance the understanding and diagnosis of cancer, as well as the development of treatment and prevention options that will ultimately lead to cures for blood cancer patients.
  Application Receipt Date(s): September 1, 2017

- **TITLE:** Scholar Award
  [http://www.lls.org/research/career-development-program](http://www.lls.org/research/career-development-program)
  **SPONSOR:** Leukemia & Lymphoma Society (LLS)
  **Synopsis:** The purpose of the Career Development Program (CDP) is to enhance the careers of scientists researching
Each SCOR is comprised of a minimum of three scientific Projects and a minimum of two scientific Cores that will cooperate to achieve the overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics. Application Receipt Date(s): Multiple dates, see announcement

**Synopsis:**

- **SPONSOR:** Leukemia & Lymphoma Society (LLS)
- **TAG:** Title: Gene Fusions in Pediatric Sarcomas (R01)

**SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI)

**Synopsis:**

- **SPONSOR:** Leukemia & Lymphoma Society (LLS)
- **TAG:** Title: Academic Grants: Career Development Program - Special Fellow Award

**Synopsis:**

- **SPONSOR:** American Skin Association
- **TAG:** Title: Medical Student Grants Targeting Melanoma and Skin Cancer

**Synopsis:**

- **SPONSOR:** Leukemia & Lymphoma Society (LLS)
- **TAG:** Title: Academic Grants: Career Development Program - Fellow Award

**Synopsis:**

- **SPONSOR:** Leukemia & Lymphoma Society (LLS)
- **TAG:** Title: Specialized Center of Research Program

**Synopsis:**

- **SPONSOR:** Leukemia & Lymphoma Society (LLS)

**Synopsis:**

- **SPONSOR:** Leukemia & Lymphoma Society (LLS)
under the leadership of a SCOR Director. There must be objective evidence of interdisciplinary research among the Projects and Cores.

Application Receipt Date(s): September 22, 2017

• **TITLE:** Adolescent/Young Adult Cooperative Group Correlative Studies Grant  
  [http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8490965](http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8490965)  
  **SPONSOR:** Lymphoma Research Foundation (LRF)  
  Application Receipt Date(s): September 6, 2017

• **TITLE:** Mantle Cell Lymphoma Therapeutic Studies Grant  
  [http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8490965](http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8490965)  
  **SPONSOR:** Lymphoma Research Foundation (LRF)  
  Application Receipt Date(s): September 6, 2017

• **TITLE:** Advancing the Science of Geriatric Palliative Care (R01)  
  **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)  
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.  
  Application Receipt Date(s): Multiple dates, see announcement

• **TITLE:** End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) With Serious Illnesses (R01)  
  **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)  
  **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 - 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.  
  Application Receipt Date(s): Multiple dates, see announcement

• **TITLE:** Arts-Based Approaches in Palliative Care for Symptom Management (R01)  
  **SPONSOR:** United States Department of Health and Human Services (HHS), National Institutes of Health (NIH)  
  **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to support mechanistic clinical studies aimed at understanding the impact of arts-based approaches in palliative care for symptom management. This FOA is intended to support mechanistic clinical studies to provide an evidence base for the use of the arts in palliative care for symptom management. The objective is to understand the biological, physiological, neurological, psychological, and/or sociological mechanisms by which the arts exert their effects on symptom management during and throughout the palliative care continuum. The goal is for the research supported under this FOA to develop an evidence-base that could be used as a basis for the uptake of arts-based therapies in palliative care settings, among individuals across the lifespan, with a wide variety of serious chronic conditions and their accompanying symptoms. This FOA is not intended to determine efficacy or the comparative effectiveness of interventions, or to assess interventions designed to treat the underlying cause of a particular disease state.  
  Application Receipt Date(s): Multiple dates, see announcement

• **TITLE:** Consortium Linking Oncology with Thrombosis (CLOT) (U01)  
  **SPONSOR:** National Heart, Lung, and Blood Institute  
  Application Receipt Date(s): October 23, 2017

• **TITLE:** Limited Competition: Research Resource for Systematic Reviews of Complementary and Integrative Health (R24)  
  [RFA-AT-17-003](https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-17-003.html)  
  **SPONSOR:** National Center for Complementary and Integrative Health  
  Application Receipt Date(s): August 21, 2017

• **TITLE:** Expanding Genome Integrity Assays to Population Studies (U01)  
  **SPONSOR:** National Institute of Environmental Health Sciences, National Cancer Institute  
  **Synopsis:** The funding opportunity announcement (FOA) will support development and pilot testing of assays, such as DNA repair capacity or mutation detection, that will facilitate the wider use of genome integrity investigation in epidemiological
and population studies.
Application Receipt Date(s): October 13, 2017

- **TITLE:** Academic Development of a Training Program for Good Laboratory Practices in High Containment Environments (U24)  
  *(RFA-FD-17-013)*  
  **SPONSOR:** Food and Drug Administration  
  **Synopsis:** The Food and Drug Administration (FDA) is announcing the availability of cooperative agreement funds for the support of a Funding Opportunity Announcement (FOA) entitled "Academic Development of a Training Program for Good Laboratory Practices in High Containment Environments (U24)." In this FOA, FDA announces its intention to accept and consider a single source application for an award to the University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL) for the development and implementation of a certified, academic training course for instruction in Good Laboratory Practices (GLP) in a Biosafety Level (BSL) 4 High Containment Environment. FDA seeks to support an effort to design a robust, collaborative, and educational program using problem-based learning techniques designed to bring researchers and regulators together to educate each other on the challenges related to these issues and to identify solutions that are acceptable from both scientific and regulatory perspectives.  
  Application Receipt Date(s): August 29, 2017

- **TITLE:** Global Pediatric Clinical Trials Network (U18)  
  *(RFA-FD-17-014)*  
  **SPONSOR:** Food and Drug Administration  
  **Synopsis:** The goals of this program are to support the development of the scientific infrastructure needed to plan and execute pediatric clinical trials through collaboration with stakeholders from academia, industry, parent/patient advocacy groups, and government agencies. The Global Pediatric Trial Network should be a coordinating resource for pediatric product development with sustainable global infrastructure to plan, start up, conduct, and close out pediatric clinical investigations. There should be an emphasis on operational efficiency and network sustainability with early, systematic, and integrative approaches to pediatric studies.  
  Application Receipt Date(s): August 22, 2017

- **TITLE:** Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEER) (RM1)  
  *(RFA-HG-17-006)*  
  **SPONSOR:** National Human Genome Research Institute  
  Application Receipt Date(s): October 31, 2017

- **TITLE:** Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)  
  *(RFA-NS-17-024)*  
  **SPONSOR:** National Institute of Neurological Disorders and Stroke  
  Application Receipt Date(s): September 1, 2017

**PROGRAM ANNOUNCEMENTS**

- **TITLE:** Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)  
  *(RFA-NS-17-024)*  
  **SPONSOR:** National Institute of Neurological Disorders and Stroke  
  Application Receipt Date(s): September 1, 2017

- **TITLE:** Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21, R03, R01)  
  *(PA-17-323) (PA-17-324) (PA-17-325)*  
  **SPONSOR:** National Human Genome Research Institute  
  **National Cancer Institute**  
  **National Institute on Aging**  
  **National Institute of Allergy and Infectious Diseases**  
  **National Institute of Environmental Health Sciences**  
  **National Institute on Minority Health and Health Disparities**  
  **National Institute of Neurological Disorders and Stroke**  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.  
  Application Receipt/Submission Date(s): Multiple dates, see announcement

**OTHER FUNDING OPPORTUNITIES**  
(Sponsors in bold are NIH Peer Reviewed Organizations)
• **TITLE:** Chronic Pain Medicine Research Grant  
  [https://www.asra.com/page/70/chronic-pain-medicine-research-grant-submission-criteria](https://www.asra.com/page/70/chronic-pain-medicine-research-grant-submission-criteria)  
  **SPONSOR:** American Society of Regional Anesthesia and Pain Medicine (ASRA)

• **TITLE:** Research Grant Funding (RE01)  
  [http://www.onsfoundation.org/apply/re/RE01](http://www.onsfoundation.org/apply/re/RE01)  
  **SPONSOR:** Oncology Nursing Society (ONS), Oncology Nursing Society (ONS) Foundation

• **TITLE:** Foundation Research Grants  
  [http://www.napnapfoundation.org/napnapfoundation/grantsscholarships/grantsscholarships](http://www.napnapfoundation.org/napnapfoundation/grantsscholarships/grantsscholarships)  
  **SPONSOR:** National Association of Pediatric Nurse Practitioners, Inc. (NAPNAP), NAPNAP Foundation